Sign in

    Tom McGovern

    Research Analyst at Maxim Group

    Tom McGovern is an Equity Research Associate at Maxim Group, specializing in the finance sector with a focus on companies such as cbdMD and those involved in THC-infused beverages. He has delivered notable calls, including a 'Buy' rating for cbdMD with a target price implying a potential upside exceeding 220%, demonstrating a keen ability to identify growth opportunities. Since joining Maxim Group, McGovern has contributed to expanding research coverage in emerging markets and has established a track record for rigorous analysis. He holds relevant securities industry credentials and remains actively engaged in company evaluation and performance forecasting.

    Tom McGovern's questions to Nutex Health (NUTX) leadership

    Tom McGovern's questions to Nutex Health (NUTX) leadership • Q3 2024

    Question

    Tom McGovern from Maxim Group asked for an update on the timeline for the remaining 2024 hospital openings, the expected cadence for 2025 openings, new services being introduced to drive patient volume, details on cost-saving initiatives, and the status of removing two variable interest entities (VIEs) from the balance sheet.

    Answer

    Executive Thomas Vo confirmed one hospital is on track for a November opening, while the second, located in Florida, might be slightly delayed into early 2025 due to a hurricane but is still targeted for December. For 2025, he expects one hospital in Q1/Q2 and three by year-end. He also mentioned exploring new services like personal injury and wellness. COO Joshua DeTillio detailed cost-saving efforts in labor, supply chain (targeting a 15% reduction), and contract services, highlighting new software for labor analytics and scheduling. Thomas Vo concluded that the bank intends to remove the final two VIEs by the end of the year.

    Ask Fintool Equity Research AI